Open access
Open access
Powered by Google Translator Translator

Diabetes

RCT | Best endovascular treatment first strategy yields better outcomes for chronic limb ischemia vs. vein bypass first strategy

3 May, 2023 | 15:39h | UTC

A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial – The Lancet

Commentary: BASIL-2 Supports Endo-First Strategy for CLTI With Infrapopliteal Disease – TCTMD

 


RCT | Intermittent fasting plus early time-restricted eating vs. calorie restriction and standard care in adults at risk of type 2 DM

24 Apr, 2023 | 13:07h | UTC

Intermittent fasting plus early time-restricted eating versus calorie restriction and standard care in adults at risk of type 2 diabetes: a randomized controlled trial – Nature Medicine (if the link is paywalled, try this one)

News Release: Fasting diet reduces risk markers of type 2 diabetes – University of Adelaide

Related:

RCT | Time-restricted eating not more effective than daily calorie restriction for managing nonalcoholic fatty liver disease

Health effects of the time-restricted eating in adults with obesity: A systematic review and meta-analysis – Frontiers in Nutrition

Time-restricted eating and exercise training improve HbA1c and body composition in women with overweight/obesity: A randomized controlled trial – Cell Metabolism

Effectiveness of Early Time-Restricted Eating for Weight Loss, Fat Loss, and Cardiometabolic Health in Adults With Obesity: A Randomized Clinical Trial – JAMA Internal Medicine

Effects of Intermittent Fasting in Human Compared to a Non-intervention Diet and Caloric Restriction: A Meta-Analysis of Randomized Controlled Trials – Frontiers in Nutrition

Time-Restricted Eating: Integrating The What With The When – Advances in Nutrition

Calorie Restriction with or without Time-Restricted Eating in Weight Loss- New England Journal of Medicine

Intermittent Fasting and Obesity-Related Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials – JAMA Network Open

 

Commentary on Twitter

 


Study estimates poor diet causes 70% of diabetes cases globally

21 Apr, 2023 | 13:06h | UTC

Incident type 2 diabetes attributable to suboptimal diet in 184 countries – Nature Medicine

News Release: Study links poor diet to 14 million cases of type 2 diabetes globally – Tufts University

 

Commentary on Twitter

 


M-A | Adverse events related to tirzepatide (a dual GIP/GLP-1 receptor agonist)

21 Apr, 2023 | 12:59h | UTC

Adverse Events Related to Tirzepatide – Journal of the Endocrine Society

Related:

RCT | Safety and efficacy of Tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan.

Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis – Diabetologia

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

 


Review | Current practice in the perioperative management of patients with diabetes mellitus

18 Apr, 2023 | 13:19h | UTC

Current practice in the perioperative management of patients with diabetes mellitus: a narrative review – British Journal of Anaesthesia

Related:

Guideline Summary: New guidance on the perioperative management of diabetes.

Perioperative Evaluation and Management of Endocrine Disorders – Mayo Clinic Proceedings

Recent advances in diabetes treatments and their perioperative implications – Current Opinion in Anesthesiology

Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes – Anesthesiology

 


Review | Diagnosis and management of prediabetes

12 Apr, 2023 | 13:28h | UTC

Diagnosis and Management of Prediabetes: A Review – JAMA (free for a limited period)

Editorial: Prediabetes Diagnosis and Management – JAMA (free for a limited period)

Video: Screening for Prediabetes – JAMA

Audio Clinical Review: Diagnosis and Management of Patients With Prediabetes – JAMA

 


Single arm trial | Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography

12 Apr, 2023 | 13:06h | UTC

Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial – Cardiovascular Diabetology

 


M-A | Benefits and harms of drug treatment for type 2 diabetes

10 Apr, 2023 | 14:03h | UTC

Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials – The BMJ

 


Swiss recommendations for the treatment of type 2 diabetes mellitus

10 Apr, 2023 | 13:50h | UTC

Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023) – Swiss Medical Weekly

Related: Guideline | ADA 2023 Standards of Medical Care in Diabetes.

 


Cohort Study | Pregnancy glucose intolerance, even below diabetes criteria, linked to increased risk of type 2 diabetes

5 Apr, 2023 | 13:42h | UTC

Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

 


M-A | Efficacy of flash glucose monitoring in type 1 and type 2 diabetes

5 Apr, 2023 | 12:46h | UTC

Efficacy of Flash Glucose Monitoring in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials – Frontiers in Clinical Diabetes and Healthcare

 


Single-arm study | Transcatheter arterialization of deep veins may help avoid amputation in chronic limb-threatening ischemia

3 Apr, 2023 | 14:03h | UTC

Transcatheter Arterialization of Deep Veins in Chronic Limb-Threatening Ischemia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

New procedure helps patients avoid leg amputation – Vanderbilt University

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI – TCTMD

Transcatheter Arterialization Could Revolutionize Treatment of Limb-Threatening Ischemia – HCP Live

Transcatheter Arterialization for Limb Ischemia – American College of Cardiology

 

Commentary on Twitter

 


M-A | Effects of statin therapy on glycemic control and insulin resistance

31 Mar, 2023 | 13:45h | UTC

Effects of statin therapy on glycemic control and insulin resistance: A systematic review and meta-analysis – European Journal of Pharmacology

Related:

Cohort study: Statin therapy initiation linked to increased risk of diabetes progression.

Meta-Analysis: Medications that Reduce or Increase the Risk of New Onset Diabetes

Observational Study Points to an Increased Risk of Diabetes Among Patients Using Statins

Another Observational Study Showing Association of Statin Use with Risk of New‐Onset Diabetes Mellitus

Cohort Study: Statin Use Associated with a 38% Higher Risk of Incident Type 2 Diabetes

 


Phase 2 RCT | Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes

30 Mar, 2023 | 14:08h | UTC

Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

 


SR | Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy

29 Mar, 2023 | 13:15h | UTC

Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy – Cochrane Library

Summary: Injections of anti-vascular endothelial growth factor for advanced diabetic retinopathy – Cochrane Library

 


Podcast | Diabetes updates

29 Mar, 2023 | 13:09h | UTC

#387: Diabetes Updates with Dr. Marie McDonnell: New Tools for the New Rules – The Curbsiders

 


A syndrome-specific antibiotic stewardship intervention reduced antipseudomonal antibiotic use in diabetic foot infections

29 Mar, 2023 | 13:10h | UTC

Impact of a syndrome-specific antibiotic stewardship intervention on antipseudomonal antibiotic use in inpatient diabetic foot infection management – Antimicrobial Stewardship & Healthcare Epidemiology

 


Practical guide to glucocorticoid induced hyperglycemia and diabetes

28 Mar, 2023 | 14:35h | UTC

Practical Guide to Glucocorticoid Induced Hyperglycaemia and Diabetes – Diabetes Therapy

 


Exploratory analysis | Hypoglycemia incidence is lower with linagliptin vs. glimepiride in patients with early type 2 DM

22 Mar, 2023 | 13:15h | UTC

Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial – Diabetes, Obesity and Metabolism

Original Study: Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial – JAMA

 


RCT | Closed-loop insulin delivery system enhances blood sugar control in young children with type 1 diabetes

20 Mar, 2023 | 13:54h | UTC

Summary: The study enrolled 102 young children between ages 2 and 5, randomized in a 2:1 ratio to either a closed-loop control system of insulin delivery (“artificial pancreas”) or a standard care comparison group. During the 13 weeks of study follow-up, participants in the artificial pancreas group spent 12% more time within their target blood glucose range compared to the standard care group.

The closed-loop group experienced two cases of severe hypoglycemia, while the standard-care group had one case. In the closed-loop group, one case of diabetic ketoacidosis occurred due to a problem with the insulin pump.

Article: Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

News Releases:

Artificial Pancreas Developed at UVA Improves Blood Sugar Control for Kids Ages 2-6, Study Finds – University of Virginia

NIH-supported trial shows artificial pancreas improves blood glucose control in young children – National Institutes of Health

 

Commentary on Twitter

 


M-A | Global prevalence of diabetic retinopathy in pediatric type 2 diabetes

20 Mar, 2023 | 13:12h | UTC

Global Prevalence of Diabetic Retinopathy in Pediatric Type 2 Diabetes: A Systematic Review and Meta-analysis – JAMA Network Open

 


Post-hoc analysis | Could SGLT2 inhibitors have a beneficial effect on gout symptoms?

17 Mar, 2023 | 13:02h | UTC

Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without GoutA Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER – JAMA Cardiology

Related: Post-hoc analysis | Can SGLT2 inhibitors reduce the risk of hyperuricemia and gout?

 


RCT | Insulin degludec is noninferior to insulin detemir for the treatment of pregnant women with type 1 diabetes

16 Mar, 2023 | 12:59h | UTC

Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

 


The global burden of metabolic disease: data from 2000 to 2019

13 Mar, 2023 | 14:39h | UTC

The global burden of metabolic disease: Data from 2000 to 2019 – Cell Metabolism (free for a limited period)

 


Current recommendations for management of pediatric diabetic ketoacidosis

10 Mar, 2023 | 14:38h | UTC

Current recommendations for management of paediatric diabetic ketoacidosis – Canadian Pediatric Society

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.